TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24946226
Drug: Topical clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin mouthwash
Study: 19582577
Drug: Assistant-administered abdominal
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assistant-administered abdominal pressure
Study: 15921866
Drug: Felodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5 mg/d)
Study: 9470315
Drug: Captopril 100
Normalized name: captopril 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 100 mg (Group 3)
Study: 23558909
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy (GDT)
Study: 24935686
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g of ethanol/kilogram bodyweight, taken orally immediately before lights off
Study: 21529370
Drug: Depression Recognition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depression Recognition and Treatment package (DepReT-Stroke) in addition to treatment as usual (TAU)
Study: 19195498
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg once a day
Study: 19195498
Drug: atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 40 mg once a day
Study: 7892024
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (EM) 4 mg administered via the L2-L3 intervertebral space
Study: 7892024
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (EM) 4 mg administered pre-trauma
Study: 3287226
Drug: Defibrotide at
Normalized name: defibrotide
DrugBank: Defibrotide (DB04932)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Defibrotide at a dose of 400 mg b.i.d. i.v. in 50 ml phleboclysis in 5 minutes (n = 108)
Study: 3287226
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin at a dose of 5000 IU t.i.d. subcutaneously (n = 103)
Study: 31898965
Drug: WBC count
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WBC count at baseline (per 1 × 10^9/L increase)
Study: 30501618
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of intravenous dexamethasone and 1 dose of normal saline (Group B)
Study: 23827107
Drug: Injection/oral itraconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection/oral itraconazole
Study: 15571210
Drug: Bumetanide 4
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bumetanide 4 mg/day
Study: 29475008
Drug: rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20 mg/day (R20)
Study: 29475008
Drug: atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 10 mg/day combined with ezetimibe 10 mg/day (A10 + E10)
Study: 27496680
Drug: Thalidomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (200 mg daily)
Study: 18454864
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics for 8 days
Study: 14551179
Drug: Ragaglitazar 4
Normalized name: Ragaglitazar
DrugBank: Ragaglitazar (DB06533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragaglitazar 4 mg for 21 days in patients with type 2 diabetes
Study: 14551179
Drug: Ragaglitazar (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ragaglitazar (various doses 0.5-16 mg) for healthy subjects
Study: 8792760
Drug: antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: antidepressant treatment (amitriptyline hydrochloride, fluoxetine hydrochloride, toloxatone)
Study: 7552929
Drug: Topical levocabastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical levocabastine
Study: 8101534
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered terfenadine
Study: 27448679
Drug: Intravenous-to-oral solithromycin
Normalized name: roxithromycin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous-to-oral solithromycin
Study: 27448679
Drug: Intravenous-to-oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous-to-oral moxifloxacin
Study: 14512102
Drug: Higher methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher methadone doses (more than 80 mg)
Study: 14512102
Drug: Psychopharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychopharmacological treatment associated with methadone
Study: 14512102
Drug: Weekly or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly or twice weekly methadone administration
Study: 10855941
Drug: Prolonged courses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged courses of steroids
Study: 10855941
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A and cytotoxic agents
Study: 10855941
Drug: Pulse methylprednisolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse methylprednisolone, azathioprine, tacrolimus, mycophenolate mofetil, combination therapy
Study: 25192967
Drug: Mean oral
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean oral morphine intake
Study: 20200939
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg) before exercise
Study: 20200939
Drug: Placebo before,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo before, ibuprofen after
Study: 17881719
Drug: CEP-1347 10
Normalized name: CEP-1347
DrugBank: CEP-1347 (DB05403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEP-1347 10 mg BID
Study: 17881719
Drug: CEP-1347 25
Normalized name: CEP-1347
DrugBank: CEP-1347 (DB05403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEP-1347 25 mg BID
Study: 17881719
Drug: CEP-1347 50
Normalized name: CEP-1347
DrugBank: CEP-1347 (DB05403)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEP-1347 50 mg BID
Study: 15674304
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (males: 300 ml/day, 38.3 g alcohol/day; females: 200 ml/day, 25.5 g alcohol/day)
Study: 23554113
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg once daily for 5 days
Study: 18339162
Drug: Propofol 1
Normalized name: propofol 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1 mg/kg
Study: 7788197
Drug: Thiopentone 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone 1.5 mg/kg
Study: 12123540
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg daily
Study: 15146102
Drug: Combined conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined conjugated equine estrogen 0.625 mg and medroxyprogesterone acetate 5 mg daily (CCEP)
Study: 11593317
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with doxorubicin/G-CSF followed by high-dose chemotherapy (HDC) with CTCb and melphalan, and dose-escalated paclitaxel at 475 mg/m2
Study: 9817491
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional treatment (CABG alone)
Study: 18463448
Drug: 2‐compound scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐compound scalp formulation (calcipotriol plus betamethasone dipropionate)
Study: 17337492
Drug: Telmisartan 40/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40/80 mg
Study: 12900588
Drug: Losartan 50/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50/100 mg
Study: 31505986
Drug: Locally acting
Normalized name: Corticosteroids acting locally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locally acting generic drug (T)
Study: 31505986
Drug: Innovator drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovator drug (R)
Study: 29570772
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg daily aspirin for 3 years
Study: 29570772
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg daily aspirin for 3 years
Study: 7341219
Drug: Atropine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.5 mg s.c.)
Study: 7341219
Drug: Neostigmine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (0.5 mg s.c.)
Study: 27553192
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin lispro
Study: 22385260
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg systemic doxycycline (DOXY) for 7 days after surgery
Study: 19670918
Drug: pioglitazone (15-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone (15-45 mg once daily)
Study: 17454066
Drug: Galantamine hydrobromide
Normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Galantamine hydrobromide dispersible tablet (10 mg)
Study: 17454066
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (conventional tablet)
Study: 15281473
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous nasal spray (64 microg/d)
Study: 12215757
Drug: Ximelagatran/Melagatran (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran/Melagatran (highest dose)
Study: 12215757
Drug: Ximelagatran/Melagatran (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran/Melagatran (24 mg, twice daily)
Study: 12215757
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg, once daily)
Study: 12215757
Drug: Dalteparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (5000 IE, once daily)
Study: 12215757
Drug: Melagatran (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melagatran (3 mg, twice daily)
Study: 9579164
Drug: Regular inhaled
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular inhaled corticosteroids
Study: 8563223
Drug: IgA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgA and IgG gliadin antibodies (AGA) and IgA endomysium antibodies (EMA) in coeliac disease (CD)
Study: 657100
Drug: G.A.T.L.A. protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: G.A.T.L.A. protocol (vincristine-prednisone plus surgery and/or radiotherapy, craniocervical radiotherapy, intrathecal methotrexate, anti-leukemia and anti-lymphoma treatments)
Study: 657100
Drug: No uniform
Approvals — FDA: no, EMA: no, PMDA: no
Description: No uniform treatment (1966-1972 group)
Study: 31489024
Drug: Micro‐traumatic evacuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro‐traumatic evacuation of cerebral hemorrhage with conventional symptomatic treatment (Control)
Study: 17874489
Drug: Coitus at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coitus at least once weekly
Study: 15181067
Drug: Troglitazone, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone, 400 mg/d (early intervention)
Study: 3706675
Drug: New inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: New inhalation technique (shrug of the shoulder method)
Study: 3706675
Drug: Conventional inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional inhalation technique
Study: 30498336
Drug: Cucumis sativus
Normalized name: CUCUMIS SATIVUS LEAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cucumis sativus extract (CSE) 10 mg twice daily
Study: 30498336
Drug: Glucosamine-chondroitin (GC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine-chondroitin (GC) 1,350 mg twice daily
Study: 20965814
Drug: Standard anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anticoagulant intensity with warfarin (INR maintained between 2.0 and 3.0)
Study: 7865650
Drug: Phenolphthalein glucuronide
Normalized name: menthol glucuronide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenolphthalein glucuronide equivalent to 30 mg phenolphthalein
Study: 7865650
Drug: Phenolphthalein (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenolphthalein (doses of 15, 30, 45, 60, 75, and 90 mg)
Study: 7865650
Drug: Phenolphthalein glucuronide
Normalized name: menthol glucuronide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenolphthalein glucuronide (doses of 24, 48, 72, 96, 120, and 144 mg)
Study: 2802557
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg) twice daily for 3 days
Study: 2802557
Drug: Ofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (200 mg) twice daily for 7 days
Study: 2802557
Drug: Ofloxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (300 mg) twice daily for 7 days
Study: 2802557
Drug: Trimethoprim-sulfamethoxazole (160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (160/800 mg) twice daily for 7 days
Study: 1096686
Drug: Pyridoxine therapy
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine therapy (200 mg daily)
Study: 31629372
Drug: Oral Zhiqiao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Zhiqiao Gancao (ZQGC) decoction
Study: 31629372
Drug: Oral anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-inflammatory drug celecoxib
Study: 23324098
Drug: AZD1940 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1940 (400 μg)
Study: 23324098
Drug: AZD1940 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD1940 (800 μg)
Study: 20971614
Drug: GH+Ox 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH+Ox 0.03 mg/kg/d
Study: 20971614
Drug: GH+Ox 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH+Ox 0.06 mg/kg/d
Study: 19935025
Drug: Periodontal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal treatment starting around 20 weeks of gestation (n=542)
Study: 19935025
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving no treatment until 6 weeks after pregnancy (n=540)
Study: 16908486
Drug: TGN1412 (anti-CD28
Approvals — FDA: no, EMA: no, PMDA: no
Description: TGN1412 (anti-CD28 monoclonal antibody)
Study: 11710402
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (Cr) 20 g for 5 days
Study: 26283229
Drug: SMS text
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS text reminders for adherence to artemether-lumefantrine and post-treatment review
Study: 23507773
Drug: 20 IU
Normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU of intranasal insulin
Study: 23507773
Drug: 40 IU
Normalized name: Oxytocin 40 IU/1 ML Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 IU of intranasal insulin
Study: 23507773
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (both doses)
Study: 16899712
Drug: Water (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (240 ml)
Study: 9040055
Drug: MCAF/MCP-1 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCAF/MCP-1 in myocardial infarction at 3 hours (133 +/- 19 pg/ml)
Study: 9040055
Drug: MCAF/MCP-1 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCAF/MCP-1 in myocardial infarction at 9 hours (143 +/- 20 pg/ml)
Study: 9040055
Drug: MCAF/MCP-1 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCAF/MCP-1 in myocardial infarction at 24 hours (168 +/- 13 pg/ml)
Study: 3309198
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy as prophylaxis
Study: 23672224
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine
Study: 27853872
Drug: Psychosomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosomatic treatment for the elderly (5-week therapy)
Study: 24477298
Drug: EVEN protein
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: EVEN protein distribution (31.5 ± 1.3 g at breakfast, 29.9 ± 1.6 g at lunch, 32.7 ± 1.6 g at dinner)
Study: 24477298
Drug: SKEW protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKEW protein distribution (10.7 ± 0.8 g at breakfast, 16.0 ± 0.5 g at lunch, 63.4 ± 3.7 g at dinner)
Study: 22704410
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba leaf tablets, 19.2 mg each dose, taken 3 times a day for 6 months
Study: 20728068
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard analgesic administration)
Study: 18462573
Drug: SSRIs +
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs + Cognitive Behaviour Therapy (CBT)
Study: 20201179
Drug: Rocuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.1 mg/kg
Study: 23877864
Drug: Succinylcholine 1
Normalized name: Succinylcholine 124 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1 mg/kg
Study: 8832448
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg/kg, Atracurium 0.5 mg/kg, Succinylcholine 1 mg/kg
Study: 20515217
Drug: Interpersonal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal therapy
Study: 6381019
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of a mean of 298 mg levodopa and benserazide plus 17 mg bromocriptine
Study: 6381019
Drug: Mean dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean dosage of 444 mg levodopa and benserazide
Study: 24335227
Drug: Intravenous tissue-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue-type plasminogen activator (tPA) plus endovascular therapy
Study: 24335227
Drug: Intravenous tPA
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tPA therapy alone
Study: 15864937
Drug: Tramadol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol infusion (1 mg/kg loading dose at skin closure and 0.2 mg/kg/h postoperative infusion)
Study: 15864937
Drug: Morphine PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine PCA alone (control group received saline infusion)
Study: 9088586
Drug: Frusemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (40 mg daily for 4 days)
Study: 8154887
Drug: Continuous treatment
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous treatment with 5'-DFUR at a daily oral dose of 600 mg/patient
Study: 8154887
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment with 5'-DFUR for 2 weeks at a daily oral dose of 1,200 mg/patient followed by 2 weeks of no treatment
Study: 8154887
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment regimens (continuous and intermittent)
Study: 14499204
Drug: Primidone 250
Normalized name: primidone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primidone 250 mg/day (G 250)
Study: 14499204
Drug: Primidone 750
Normalized name: Primidone
DrugBank: Primidone (DB00794)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primidone 750 mg/day (G 750)
Study: 6756932
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg b.i.d. (twice daily)
Study: 4054194
Drug: Metoprolol 200
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 200 mg once daily
Study: 6756932
Drug: Chlorthalidone 25
Normalized name: chlorthalidone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg added after 2 weeks of Metoprolol 100 mg b.i.d.
Study: 6756932
Drug: Metoprolol 200
Normalized name: metoprolol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 200 mg b.i.d. (twice daily)
Study: 29913292
Drug: Single-level transforaminal
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-level transforaminal lumbar interbody fusion (TLIF) for Group L (non-kyphotic alignment)
Study: 22051941
Drug: PHEN/TPM CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHEN/TPM CR 3.75/23 mg
Study: 22051941
Drug: PHEN/TPM CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHEN/TPM CR 15/92 mg
Study: 19652065
Drug: Trabectedin 0.58
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 0.58 mg/m² 3-hour IV infusion every week for 3 weeks of a 4-week cycle (qwk 3-hour)
Study: 6352278
Drug: Levonantradol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonantradol (0.5 mg)
Study: 6352278
Drug: Levonantradol (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonantradol (higher doses)
Study: 28661585
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 U/mL (Gla‐300)
Study: 28661585
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 U/mL (Gla‐100)
Study: 18161398
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg twice a day)
Study: 20723260
Drug: Fesoterodine 8
Normalized name: fesoterodine 8 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 8 mg
Study: 11426582
Drug: Pravastatin (10‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10‐20 mg/day)
Study: 31005386
Drug: Phenytoin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (20 mg/kg intravenous or intraosseous infusion over 20 min)